Acadia Pharmaceuticals (ACAD) Shares Outstanding (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Shares Outstanding (Entity) of $171.1 million for Q1 2026, up 2.38% year-over-year from $167.1 million in Q1 2025, and little changed quarter-over-quarter from $170.3 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Shares Outstanding (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $171.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.38% year-over-year to $171.1 million; the TTM figure through Mar 2026 stood at $171.1 million (up 2.38% YoY), while the FY2025 annual figure was $170.3 million, up 2.16% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $171.1 million, roughly flat from $170.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $171.1 million in Q1 2026, with the low at $161654.0 in Q2 2022.
- The 5-year median for Shares Outstanding (Entity) is $165.0 million (2024), against an average of $107.9 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) tumbled 99.9% in 2022, then surged 101664.05% in 2024.
- Acadia Pharmaceuticals' Shares Outstanding (Entity) stood at $161683.0 in 2022, then rose by 1.32% to $163819.0 in 2023, then soared by 101664.05% to $166.7 million in 2024, then increased by 2.16% to $170.3 million in 2025, then rose by 0.46% to $171.1 million in 2026.
- Business Quant data shows ACAD's Shares Outstanding (Entity) at $171.1 million in Q1 2026, $170.3 million in Q4 2025, and $169.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 171.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 171.60 Mn |
| Mar 31, 2026 | 170.52 Mn |
| Dec 31, 2025 | 168.36 Mn |
| Sep 30, 2025 | 168.84 Mn |
| Jun 30, 2025 | 167.83 Mn |
| Mar 31, 2025 | 166.81 Mn |
| Dec 31, 2024 | 165.72 Mn |
| Sep 30, 2024 | 165.97 Mn |
| Jun 30, 2024 | 165.55 Mn |
| Mar 31, 2024 | 164.80 Mn |
| Dec 31, 2023 | 163,819.00 |
| Sep 30, 2023 | 164,234.00 |
| Jun 30, 2023 | 163,458.00 |
| Mar 31, 2023 | 162.26 Mn |
| Dec 31, 2022 | 161,683.00 |
| Sep 30, 2022 | 161,852.00 |
| Jun 30, 2022 | 161,654.00 |
| Mar 31, 2022 | 161.23 Mn |
| Dec 31, 2021 | 160.49 Mn |
| Sep 30, 2021 | 160.66 Mn |